Claims for Patent: 8,367,402

Summary for Patent: 8,367,402

Title:	Extranuclear RNA splicing in neuronal dendrites
Abstract:	The present invention relates to methods of synaptic network remodeling by means of extranuclear RNA splicing. The present invention also provides methods of extranuclear RNA splicing, and methods of protein translation based on extranuclear RNA splicing.
Inventor(s):	Eberwine; James (Philadelphia, PA), Miyashiro; Kevin (Philadelphia, PA), Glanzer; Jason (Omaha, NE)
Assignee:	The Trustees of the University of Pennsylvania (Philadelphia, PA)
Application Number:	12/628,860
Patent Claims:	1. A method of remodeling a dendrite, said method comprising: transfecting a dendrite with an RNA comprising at least one intron, wherein said dendrite comprises at least one component of a spliceosome and further wherein said at least one component of a spliceosome is capable of splicing an RNA; wherein said RNA comprising at least one intron is spliced by said at least one component of a spliceosome; wherein the at least one component of a spliceosome is selected from the group consisting of Y14, Magoh, RNPS1, SC-35, SF2, U2AF65, Smith antigen, pan-SR antigen, U1 snRNP, U2 snRNP, U4 snRNP, U5 snRNP, and U6 snRNP; and wherein said spliced RNA is translated in said dendrite; and wherein said dendrite is thereby remodeled as a consequence of said translation. 2. A method of remodeling a dendrite interaction, said method comprising: transfecting a dendrite with an RNA comprising at least one intron, wherein said dendrite comprises at least one component of a spliceosome and further wherein said at least one component of a spliceosome is capable of splicing an RNA; wherein said RNA comprising at least one intron is spliced by said at least one component of a spliceosome; wherein the at least one component of the spliceosome is selected from the group consisting of Y14, Magoh, RNPS1, SC-35, SF2, U2AF65, Smith antigen, pan-SR antigen, U1 snRNP, U2 snRNP, U4 snRNP, U5 snRNP, and U6 snRNP; and wherein said spliced RNA is translated in said dendrite; and wherein said dendrite interaction is thereby remodeled as a consequence of said translation. 3. A method of remodeling a synaptic network comprising interaction with at least one dendrite, said method comprising: transfecting a dendrite with an RNA comprising at least one intron, wherein said dendrite comprises at least one component of a spliceosome and further wherein said at least one component of a spliceosome is capable of splicing an RNA; wherein said RNA comprising at least one intron is spliced by said at least one component of a spliceosome; wherein the at least one component of the spliceosome is selected from the group consisting of Y14, Magoh, RNPS1, SC-35, SF2, U2AF65, Smith antigen, pan-SR antigen, U1 snRNP, U2 snRNP, U4 snRNP, U5 snRNP, and U6 snRNP; and wherein said spliced RNA is translated in said dendrite; and wherein said synaptic network is thereby remodeled as a consequence of said translation. 4. A method of splicing an RNA, said method comprising the steps of: a. providing an isolated dendrite comprising at least one component of a spliceosome, wherein said at least one component of a spliceosome is capable of splicing an RNA, and wherein the at least one component of a spliceosome is selected from the group consisting of Y14, Magoh, RNPS1, SC-35, SF2, U2AF65, Smith antigen, pan-SR antigen, U1snRNP, U2 snRNP, U4 snRNP, U5 snRNP, and U6 snRNP; and b. transfecting said dendrite with an RNA comprising at least one intron; wherein said RNA comprising at least one intron is spliced by said at least one component of a spliceosome. 5. The method of claim 1, wherein said dendrite is a component of a neuron. 6. The method of claim 1, wherein said dendrite is an isolated dendrite. 7. The method of claim 1, wherein said RNA comprising at least one intron further comprises RNA splicing donor/acceptor pairs, and wherein the RNA splicing donor/acceptor pairs are selected from the group consisting of canonical, atypical and cryptic. 8. The method of claim 1, wherein said RNA comprising at least one intron is a pre-RNA. 9. The method of claim 8, wherein said pre-RNA is a pre-mRNA. 10. The method of claim 1, wherein said RNA comprising at least one intron is transcribed from a nucleic acid comprising a construct selected from the group consisting of pEGFP-N1, pDsRed-N1, splicing factor 1/mammalian branch point binding protein-green fluorescent protein (SF1/mBBP-GFP), U2AF65-GFP, a GFP construct, a DsRed construct, and histone 2B-YFP. 11. A method of translating an RNA, said method comprising the steps of: a. providing an isolated dendrite comprising at least one component of a spliceosome, wherein said at least one component of a spliceosome is capable of splicing an RNA, and wherein the at least one component of a spliceosome is selected from the group consisting of Y14, Magoh, RNPS1, SC-35, SF2, U2AF65, Smith antigen, pan-SR antigen, U1snRNP, U2 snRNP, U4 snRNP, U5 snRNP, and U6 snRNP; and b. transfecting said dendrite with an RNA comprising at least one intron, wherein said RNA is spliced by said at least one component of a spliceosome; further wherein said spliced RNA is translated. 12. A method of splicing an RNA, said method comprising the steps of: a. providing an isolated synaptoneurosoine comprising at least one component of a spliceosome, wherein said at least one component of a spliceosome is capable of splicing an RNA, and wherein the at least one component of a spliceosome is selected from the group consisting of Y14, Magoh, RNPS1, SC-35, SF2, U2AF65, Smith antigen, pan-SR antigen, U1 snRNP, U2 snRNP, U4 snRNP, U5 snRNP, and U6 snRNP; and b, contacting said synaptoneurosome with an RNA comprising at least one intron; wherein said RNA comprising at least one intron is spliced by said at least one component of a spliceosome. 13. A method of translating an RNA, said method comprising the steps of: a. providing an isolated synaptoneurosome comprising at least one component of a spliceosome, wherein said at least one component of the spliceosome is capable of splicing an RNA, and wherein the at least one component of a spliceosome is selected from the group consisting of Y14, Magoh, RNPS1, SC-35, SF2, U2AF65, Smith antigen, pan-SR antigen, U1 snRNP, U2 snRNP, U4 snRNP, U5 snRNP, and U6 snRNP; b. contacting said synaptoneurosome with an RNA comprising at least one intron, wherein said RNA is spliced by said at least one component of a spliceosome; and c. contacting said spliced RNA with a composition capable of translating an RNA under conditions suitable for translating an RNA.

Details for Patent 8,367,402

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2024-04-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2024-04-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2024-04-07